EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial)

Mariana S Sousa iD, Peter Martin iD, Miriam J Johnson iD, Michael Lind, Matthew Maddocks iD, Alex Bullock, Meera Agar iD, Sungwon Chang, Slavica Kochovska iD, Irina Kinchin, Deidre Morgan iD, Belinda Fazekas und 5 weitere

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0285850 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, 2023. Verfasst von Mariana S Sousa und 16 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health, Improving Palliative, Aged and Chronic Care through Clinical Research and Translation (IMPACCT), University of Technology Sydney, …. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helsinn Group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anorexia is experienced by most people with lung cancer during the course of their disease and treatment. Anorexia reduces response to chemotherapy and the ability of patients to cope with, and complete their treatment leading to greater morbidity, poorer prognosis and outcomes. Despite the significant importance of cancer-related anorexia, current therapies are limited, have marginal benefits and unwarranted side effects. In this multi-site, randomised, double blind, placebo controlled, phase II trial, participants will be randomly assigned (1:1) to receive once-daily oral dosing of 100mg of anamorelin HCl or matched placebo for 12 weeks. Participants can then opt into an extension phase to receive blinded intervention for another 12 weeks (weeks 13–24) at the same dose and frequency. Adults (≥18 years) with small cell lung cancer (SCLC); newly diagnosed with planned systemic therapy OR with first recurrence of disease following a documented disease-free interval ≥6 months, AND with anorexia (i.e., ≤ 37 points on the 12-item Functional Assessment of Anorexia Cachexia Treatment (FAACT A/CS) scale) will be invited to participate. Primary outcomes are safety, desirability and feasibility outcomes related to participant recruitment, adherence to interventions, and completion of study tools to inform the design of a robust Phase III effectiveness trial. Secondary outcomes are the effects of study interventions on body weight and composition, functional status, nutritional intake, biochemistry, fatigue, harms, survival and quality of life. Primary and secondary efficacy analysis will be conducted at 12 weeks. Additional exploratory efficacy and safety analyses will also be conducted at 24 weeks to collect data over longer treatment duration. The feasibility of economic evaluations in Phase III trial will be assessed, including the indicative costs and benefits of anamorelin for SCLC to the healthcare system and society, the choice of methods for data collection and the future evaluation design. Trial registration. The trial has been registered with the Australian New Zealand Clinical Trials Registry [ACTRN12622000129785] and approved by the South Western Sydney Local Health District Human Research Ethics Committee [2021/ETH11339]. https://clin.larvol.com/trial-detail/ACTRN12622000129785 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsAdultHumansAnorexiaQuality of LifeFeasibility StudiesAustraliaTreatment OutcomeDouble-Blind MethodRandomized Controlled Trials as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicHydrazinesOligopeptides

Substanzen

anamorelinHydrazinesOligopeptides

Autor:innen und Institutionen

  • Faculty of Health, Improving Palliative, Aged and Chronic Care through Clinical Research and Translation (IMPACCT), University of Technology Sydney, Ultimo, New South Wales, Australia.
  • School of Nursing and Midwifery, Western Sydney University, Penrith, New South Wales, Australia.
  • School of Medicine, Deakin University, Geelong, Victoria, Australia.
  • Palliative Care, Barwon Health, Geelong, Victoria, Australia.
  • Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, England.
  • Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's College London, Denmark Hill, London, United Kingdom.

ORCID-Profile: Mariana S Sousa, Peter Martin, Miriam J Johnson, Matthew Maddocks, Meera Agar, Slavica Kochovska, Deidre Morgan, David C Currow

Förderung

  • Helsinn Group

Zitieren

APA

Sousa, M. S., Martin, P., Johnson, M. J., Lind, M., Maddocks, M., Bullock, A., Agar, M., Chang, S., Kochovska, S., Kinchin, I., Morgan, D., Fazekas, B., Razmovski-Naumovski, V., Lee, J. T., Itchins, M., Bray, V., & Currow, D. C. (2023). Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial). PLOS ONE. https://doi.org/10.1371/journal.pone.0285850

Vancouver

Sousa MS, Martin P, Johnson MJ, Lind M, Maddocks M, Bullock A, et al. Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial). PLOS ONE. 2023. doi:10.1371/journal.pone.0285850

BibTeX
@article{Sousa2023,
  author = {Sousa, Mariana S and Martin, Peter and Johnson, Miriam J and Lind, Michael and Maddocks, Matthew and Bullock, Alex and Agar, Meera and Chang, Sungwon and Kochovska, Slavica and Kinchin, Irina and Morgan, Deidre and Fazekas, Belinda and Razmovski-Naumovski, Valentina and Lee, Jessica T and Itchins, Malinda and Bray, Victoria and Currow, David C},
  title = {Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial)},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0285850}
}
Kostenlos starten →